Royce & Associates LP increased its position in Medidata Solutions Inc (NASDAQ:MDSO) by 45.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 416,017 shares of the company’s stock after acquiring an additional 130,352 shares during the quarter. Royce & Associates LP’s holdings in Medidata Solutions were worth $26,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of MDSO. Ark Investment Management LLC grew its holdings in shares of Medidata Solutions by 696.2% in the second quarter. Ark Investment Management LLC now owns 74,769 shares of the company’s stock worth $5,847,000 after acquiring an additional 65,378 shares during the period. Dimensional Fund Advisors LP lifted its position in Medidata Solutions by 570.2% during the second quarter. Dimensional Fund Advisors LP now owns 66,589 shares of the company’s stock valued at $5,208,000 after purchasing an additional 56,653 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Medidata Solutions during the second quarter valued at $227,000. The Manufacturers Life Insurance Company lifted its position in Medidata Solutions by 177.8% during the second quarter. The Manufacturers Life Insurance Company now owns 117,884 shares of the company’s stock valued at $9,219,000 after purchasing an additional 75,443 shares in the last quarter. Finally, Bank of Nova Scotia lifted its position in Medidata Solutions by 7.7% during the second quarter. Bank of Nova Scotia now owns 8,365 shares of the company’s stock valued at $654,000 after purchasing an additional 600 shares in the last quarter. 97.52% of the stock is owned by institutional investors.
In other news, Director Carlos Dominguez sold 9,066 shares of Medidata Solutions stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the sale, the director now directly owns 66,020 shares of the company’s stock, valued at $4,413,437. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $65.40, for a total value of $130,800.00. Following the completion of the sale, the chief financial officer now directly owns 91,775 shares in the company, valued at $6,002,085. The disclosure for this sale can be found here. Insiders sold 18,066 shares of company stock worth $1,211,682 over the last 90 days. Company insiders own 5.80% of the company’s stock.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Medidata Solutions had a return on equity of 11.59% and a net margin of 8.14%. The business had revenue of $141.20 million for the quarter, compared to the consensus estimate of $140.65 million. During the same period in the previous year, the business earned $0.33 earnings per share. The business’s revenue was up 13.4% on a year-over-year basis. sell-side analysts predict that Medidata Solutions Inc will post 0.97 EPS for the current fiscal year.
MDSO has been the topic of several analyst reports. Wells Fargo & Co lowered their target price on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating on the stock in a research report on Friday, October 27th. SunTrust Banks reiterated a “buy” rating and set a $92.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Royal Bank of Canada reiterated a “hold” rating and set a $80.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Finally, Dougherty & Co initiated coverage on Medidata Solutions in a research report on Thursday, November 2nd. They issued a “neutral” rating on the stock. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $82.07.
ILLEGAL ACTIVITY WARNING: “Medidata Solutions Inc (MDSO) Shares Bought by Royce & Associates LP” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/02/20/medidata-solutions-inc-mdso-shares-bought-by-royce-associates-lp.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.